CO2018004572A2 - Inhibidores de calicreína plasmática humana - Google Patents

Inhibidores de calicreína plasmática humana

Info

Publication number
CO2018004572A2
CO2018004572A2 CONC2018/0004572A CO2018004572A CO2018004572A2 CO 2018004572 A2 CO2018004572 A2 CO 2018004572A2 CO 2018004572 A CO2018004572 A CO 2018004572A CO 2018004572 A2 CO2018004572 A2 CO 2018004572A2
Authority
CO
Colombia
Prior art keywords
plasma kallikrein
human plasma
kallikrein inhibitors
compounds
inhibitors
Prior art date
Application number
CONC2018/0004572A
Other languages
English (en)
Spanish (es)
Inventor
V Satish Kumar
Weihe Zhang
Lakshminarayana Vogeti
Pravin L Kotian
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of CO2018004572A2 publication Critical patent/CO2018004572A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
CONC2018/0004572A 2015-10-01 2018-04-27 Inhibidores de calicreína plasmática humana CO2018004572A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562235754P 2015-10-01 2015-10-01
PCT/US2016/054619 WO2017059178A1 (en) 2015-10-01 2016-09-30 Human plasma kallikrein inhibitors

Publications (1)

Publication Number Publication Date
CO2018004572A2 true CO2018004572A2 (es) 2018-10-31

Family

ID=58424336

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0004572A CO2018004572A2 (es) 2015-10-01 2018-04-27 Inhibidores de calicreína plasmática humana

Country Status (31)

Country Link
US (3) US10562850B2 (enExample)
EP (2) EP3355890B1 (enExample)
JP (2) JP6916171B2 (enExample)
KR (1) KR102696432B1 (enExample)
CN (2) CN108289893B (enExample)
AR (1) AR106241A1 (enExample)
AU (2) AU2016330926B2 (enExample)
CA (1) CA2999164A1 (enExample)
CO (1) CO2018004572A2 (enExample)
CY (1) CY1124907T1 (enExample)
DK (2) DK3355890T3 (enExample)
EA (2) EA202191548A1 (enExample)
ES (2) ES2985200T3 (enExample)
FI (1) FI4019022T3 (enExample)
HR (2) HRP20240557T8 (enExample)
HU (2) HUE057106T2 (enExample)
IL (3) IL291268B2 (enExample)
LT (2) LT4019022T (enExample)
MA (1) MA43052B1 (enExample)
MD (1) MD3355890T2 (enExample)
MX (2) MX385687B (enExample)
MY (1) MY198346A (enExample)
PH (2) PH12022550143A1 (enExample)
PL (2) PL4019022T3 (enExample)
PT (2) PT3355890T (enExample)
RS (2) RS65443B1 (enExample)
SG (1) SG10202003705WA (enExample)
SI (2) SI4019022T1 (enExample)
SM (2) SMT202200075T1 (enExample)
TW (2) TWI796714B (enExample)
WO (1) WO2017059178A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057106T2 (hu) * 2015-10-01 2022-04-28 Biocryst Pharm Inc Humán plazma kallikrein gátlók
JP7210540B2 (ja) 2017-08-04 2023-01-23 武田薬品工業株式会社 血漿カリクレインの阻害剤およびその使用
JP7538113B2 (ja) 2018-08-20 2024-08-21 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
CN110938077B (zh) * 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法
TW202144331A (zh) * 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
CN116444485B (zh) * 2023-03-30 2024-01-23 广西中医药大学 吡啶基取代不对称脲的非金属催化、免柱层析合成方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
DE69110787T2 (de) 1990-02-28 1996-04-04 Medtronic, Inc., Minneapolis, Minn. Intraluminale prothese mit wirkstoffeluierung.
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
EP0719334A1 (en) * 1993-09-14 1996-07-03 Genentech, Inc. Pharmaceutical compositions containing ecotin and homologs thereof
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
DE69718194T2 (de) * 1996-08-16 2003-10-16 Bristol-Myers Squibb Pharma Co., Wilmington Amidinophenyl-pyrrolidine, -pyrroline und -isoxazolidine und ihre derivate
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
AU2002341693B2 (en) * 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
DE10315377A1 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Carbonylverbindungen
BRPI0408420A (pt) * 2003-04-03 2006-03-21 Merck Patent Gmbh compostos de carbonila
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
DE102004014945A1 (de) 2004-03-26 2005-10-13 Merck Patent Gmbh Prolinylderivate
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
EP2807156A1 (en) 2012-01-27 2014-12-03 Novartis AG Aminopyridine derivatives as plasma kallikrein inhibitors
WO2013111108A1 (en) 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
KR101689093B1 (ko) 2012-06-04 2016-12-22 액테리온 파마슈티칼 리미티드 벤즈이미다졸-프롤린 유도체
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
CA2939326A1 (en) * 2014-01-14 2015-07-23 Sumitomo Dainippon Pharma Co., Ltd. Condensed 5-oxazolidinone derivative
JP6574435B2 (ja) * 2014-03-07 2019-09-11 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒト血漿カリクレイン阻害剤
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
CA2977993A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
HUE057106T2 (hu) * 2015-10-01 2022-04-28 Biocryst Pharm Inc Humán plazma kallikrein gátlók

Also Published As

Publication number Publication date
US11807605B2 (en) 2023-11-07
FI4019022T3 (fi) 2024-04-19
AU2016330926B2 (en) 2021-04-29
MX385687B (es) 2025-03-18
US10562850B2 (en) 2020-02-18
CN108289893B (zh) 2022-04-12
AU2021201924A1 (en) 2021-04-29
IL258104B (en) 2021-03-25
KR102696432B1 (ko) 2024-08-16
EP3355890B1 (en) 2021-11-10
TW201716381A (zh) 2017-05-16
JP2021169505A (ja) 2021-10-28
PL4019022T3 (pl) 2024-06-24
EP3355890A4 (en) 2019-04-24
US11066360B2 (en) 2021-07-20
EP4019022A1 (en) 2022-06-29
SMT202200075T1 (it) 2022-03-21
TWI796714B (zh) 2023-03-21
IL281066A (en) 2021-04-29
MX2018003930A (es) 2018-09-18
EA202191548A1 (ru) 2021-09-02
US20180362458A1 (en) 2018-12-20
RS62807B1 (sr) 2022-02-28
IL291268A (en) 2022-05-01
SG10202003705WA (en) 2020-06-29
IL258104A (en) 2018-05-31
SMT202400111T1 (it) 2024-05-14
SI4019022T1 (sl) 2024-06-28
AR106241A1 (es) 2017-12-27
JP7431778B2 (ja) 2024-02-15
PT3355890T (pt) 2022-01-19
LT3355890T (lt) 2021-12-27
DK3355890T3 (da) 2022-01-03
DK4019022T3 (en) 2024-02-19
IL291268B2 (en) 2023-12-01
IL291268B1 (en) 2023-08-01
IL281066B (en) 2022-04-01
AU2016330926A1 (en) 2018-04-26
HUE066999T2 (hu) 2024-10-28
KR20180058815A (ko) 2018-06-01
TWI734702B (zh) 2021-08-01
PT4019022T (pt) 2024-03-11
CN108289893A (zh) 2018-07-17
MD3355890T2 (ro) 2022-03-31
MA43052A (fr) 2021-05-12
PL3355890T3 (pl) 2022-02-21
HRP20240557T1 (hr) 2024-07-05
MA43052B1 (fr) 2021-11-30
JP6916171B2 (ja) 2021-08-11
NZ741030A (en) 2024-12-20
EA038492B1 (ru) 2021-09-07
SI3355890T1 (sl) 2022-04-29
HK1254865A1 (en) 2019-07-26
MY198346A (en) 2023-08-28
BR112018005843A2 (pt) 2018-10-16
US20220098151A1 (en) 2022-03-31
MX2021010297A (es) 2021-10-22
HUE057106T2 (hu) 2022-04-28
CN114591212B (zh) 2025-01-28
CN114591212A (zh) 2022-06-07
LT4019022T (lt) 2024-03-25
WO2017059178A1 (en) 2017-04-06
HRP20220059T1 (hr) 2022-04-15
CA2999164A1 (en) 2017-04-06
JP2018529721A (ja) 2018-10-11
CY1124907T1 (el) 2023-01-05
RS65443B1 (sr) 2024-05-31
HRP20240557T8 (hr) 2024-09-27
AU2021201924B2 (en) 2022-10-13
EA201890862A1 (ru) 2018-10-31
US20200361867A1 (en) 2020-11-19
PH12018500678A1 (en) 2018-10-01
TW202136212A (zh) 2021-10-01
EP4019022B1 (en) 2024-01-31
PH12022550143A1 (en) 2022-11-21
EP3355890A1 (en) 2018-08-08
ES2905401T3 (es) 2022-04-08
ES2985200T3 (es) 2024-11-04

Similar Documents

Publication Publication Date Title
MX2016011468A (es) Inhibidores de calicreína plasmática humana.
CO2018008916A2 (es) Compuestos de benzopirazol y análogos de estos
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CO2018011064A2 (es) Inhibidores de bromodominios
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
MX2020011542A (es) Inhibidores de cd73.
MX381342B (es) Compuestos terapeuticos inhibidores.
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
EA202091668A2 (ru) Ингибиторы калликреина плазмы человека
NZ780408A (en) Human plasma kallikrein inhibitors
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores